Biotechnology company focusing on therapies for autoimmune diseases and cancer.
Tiziana Life Sciences Ltd is a prominent biotechnology firm dedicated to advancing therapeutic solutions for human diseases within the realms of oncology and immunology. At the forefront of its research and development efforts is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody aimed at treating a spectrum of conditions including Crohn's disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, psoriasis, and rheumatoid arthritis. This innovative candidate underscores Tiziana's commitment to addressing unmet medical needs through targeted immunological interventions.
Established in 1998 and headquartered in London, United Kingdom, Tiziana Life Sciences Ltd has built a robust pipeline beyond Foralumab. The company is actively developing Milciclib (TZLS-201), a potent small molecule inhibitor targeting cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases implicated in cancer cell proliferation and malignant progression. Aditionally, Tiziana is advancing an anti-Interleukin 6 receptor (IL6R) monoclonal antibody (TZLS-501) designed to counter IL6-induced inflammation, with potential applications in treating COVID-19 patients.d.
Through strategic research initiatives and clinical development, Tiziana Life Sciences continues to pioneer transformative therapies that have the potential to significantly impact patient outcomes globally. The company's innovative approach and comprehensive portfolio reflect its dedication to leveraging biotechnological advancements in the pursuit of effective treatments for complex and challenging diseases.